Johnson & JohnsonJNJEarnings & Financial Report
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 48 on the 2025 Fortune 500 list of the largest United States corporations. In 2025, the company was ranked 42th in the Forbes Global 2000.
JNJ Q4 2025 Key Financial Metrics
营收
$24.6B
毛利润
$16.6B
营业利润
N/A
净利润
$5.1B
毛利率
67.6%
营业利润率
N/A
净利率
20.8%
同比增长
9.1%
EPS
$2.08
资金流向
Johnson & Johnson Q4 2025 Financial Summary
Johnson & Johnson reported revenue of $24.6B for Q4 2025, with a net profit of $5.1B (20.8% margin). Cost of goods sold was $8.0B, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $24.6B |
|---|---|
| Net Profit | $5.1B |
| Gross Margin | 67.6% |
| Operating Margin | N/A |
| Report Period | Q4 2025 |
Johnson & Johnson Annual Revenue by Year
Johnson & Johnson annual revenue history includes year-by-year totals (for example, 2025 revenue was $94.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $94.2B |
| 2024 | $88.8B |
| 2023 | $91.6B |
| 2022 | $94.7B |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $21.38B | $22.45B | $22.47B | $22.52B | $21.89B | $23.74B | $23.99B | $24.56B |
| 同比增长 | 7.2% | -9.3% | -12.0% | 5.5% | 2.4% | 5.8% | 6.8% | 9.1% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $171.97B | $181.09B | $178.29B | $180.10B | $193.67B | $193.39B | $192.82B | $199.21B |
| 总负债 | $101.95B | $109.55B | $108.13B | $108.61B | $115.56B | $114.92B | $113.54B | $117.67B |
| 股东权益 | $70.02B | $71.54B | $70.16B | $71.49B | $78.11B | $78.47B | $79.28B | $81.54B |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $3.66B | $5.63B | $7.99B | $6.98B | $4.17B | $3.88B | $9.17B | $7.31B |
Other Health Care Companies
BMY
Bristol Myers Squibb
营收
$12.5B
净利润
$1.1B
LLY
Lilly (Eli)
营收
$19.3B
净利润
$6.6B
MRK
Merck & Co.
营收
$17.3B
净利润
$5.8B
PFE
Pfizer
营收
$16.7B
净利润
$3.5B
VTRS
Viatris
营收
$3.7B
净利润
N/A
ZTS
Zoetis
营收
$2.4B
净利润
$603.0M
ABT
Abbott Laboratories
营收
$11.4B
净利润
$1.6B
ABBV
AbbVie
营收
$15.8B
净利润
$186.0M
A
Agilent Technologies
营收
$1.9B
净利润
$434.0M
ALGN
Align Technology
营收
$995.7M
净利润
$56.8M